CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) reported Operating Margin of 8933.33% for Q1 2026, up 822551.0% on a YoY basis from N/an in Q1 2025, and up 50.13% sequentially from 17912.5% in Q4 2025.
CRISPR Therapeutics AG (CRSP) Operating Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 11 years of Operating Margin data on file, last reported at 8933.33% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 822551.0% year-over-year to 8933.33%; the trailing twelve-month figure through Mar 2026 stood at 15754.2% (down 1449501.0% YoY), and the FY2025 full-year result was 18933.65%, down 1768327.0% from the prior year.
- Operating Margin advanced to 8933.33% in Q1 2026, from 17912.5% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 34.58% in Q4 2023 to a low of 2192350.0% in Q4 2022.
- A 5-year average of 167590.53% and a median of 18103.26% in 2024 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin plunged 219122047 bps in 2022 and jumped 219238458 bps in 2023, its largest moves.
- Tracing CRSP's Operating Margin over 5 years: stood at 2192350.0% in 2022, then jumped by 100 bps to 34.58% in 2023, then tumbled by 623 bps to 180.96% in 2024, then plunged by 9798 bps to 17912.5% in 2025, then soared by 50 bps to 8933.33% in 2026.
- Business Quant data shows CRSP's Operating Margin at 8933.33% in Q1 2026, 17912.5% in Q4 2025, and 14854.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | -8,933.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,933.33% |
| Dec 31, 2025 | -17,912.50% |
| Sep 30, 2025 | -14,854.78% |
| Jun 30, 2025 | -25,708.97% |
| Mar 31, 2025 | -17,158.84% |
| Dec 31, 2024 | -180.96% |
| Sep 30, 2024 | -18,294.02% |
| Jun 30, 2024 | -29,257.25% |
| Mar 31, 2024 | -27,894.25% |
| Dec 31, 2023 | 34.58% |
| Jun 30, 2023 | -136.03% |
| Mar 31, 2023 | -64.49% |
| Dec 31, 2022 | -2,192,350.00% |
| Sep 30, 2022 | -194,029.79% |
| Jun 30, 2022 | -115,987.34% |
| Mar 31, 2022 | -18,720.43% |
| Dec 31, 2021 | -1,129.53% |
| Sep 30, 2021 | -15,637.01% |
| Jun 30, 2021 | 84.67% |
| Mar 31, 2021 | -21,251.02% |